ANAGENICS LIMITED — Board/Management Information 2016

May 8, 2016

==> picture [172 x 45] intentionally omitted <==

ASX ANNOUNCEMENT

SIGNIFICANT SCIENTIFIC APPOINTMENT FOR CELLMID ADVISORY BOARD CHAIR

SYDNEY, Monday, 9 May 2016: Cellmid Limited (ASX: CDY) congratulates Dr Bryce Vissel, the Chair of the Company’s Scientific Advisory Board, on his appointment as Professor of Neurosciences at the University of Technology Sydney.

Professor Vissel will lead a team of scientists establishing a world class research initiative at UTS in neurosciences and regenerative medicine, including Alzheimer’s and Parkinson’s disease, spinal cord disorders and neuropsychiatric conditions.

Professor Vissel has made a significant contribution to Cellmid since joining as Chair of the Company’s Scientific Advisory Board in July 2015. He has been instrumental in the development of the clinical strategy for midkine (MK), crystallised within two of the Company’s wholly owned subsidiaries Lyramid and Kinera (ASX announcement 8 April 2016).

The media release by UTS with details on Professor Vissel’s background and his new role is attached to this announcement.

End Contact: Maria Halasz, CEO T +612 92216830 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company is developing innovative novel therapies and diagnostic tests for fibrotic diseases, cancer and ischemic diseases of the heart. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel target midkine (MK) and MK antagonists globally. For further information please see www.cellmid.com.au and www.evolisproducts.com.au.

Midkine (MK)

MK is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is highly anti-apoptotic and cell protectant. It is this mechanism of action that is thought to be responsible for MK’s ability to prevent myocardial damage during ischemic events in the heart.

CELLMID LIMITED ACN 111 304 119 ASX I CDY Suite 1802, Level 18, 15 Castlereagh Street, Sydney NSW 2000 AUSTRALIA TELEPHONE +61 2 9221 6830 FACSIMILE +61 2 9221 8535 WEB www.cellmid.com.au

==> picture [536 x 77] intentionally omitted <==

Embargoed until 6 May 2016

UTS to strengthen its research in neuroscience, neurodegenerative disease and regenerative medicine

The University of Technology Sydney (UTS) is strengthening its research in neuroscience and regenerative medicine with the appointment of Professor Bryce Vissel as its Professor of Neuroscience.

Professor Vissel, who joins UTS from the Garvan Institute of Medical Research, will be responsible for developing a leading program that aims to improve the understanding and treatment of Alzheimer’s disease, Parkinson’s disease, spinal cord disorders and neuropsychiatric disorders. He will lead a group of researchers who will focus on establishing a world-class research effort in neuroscience and regenerative medicine at UTS.

“UTS recognises the enormous health, social and economic impact of neuroscience research and its value in providing insights necessary for developing treatments for devastating disorders of brain and spinal cord. Unless treatments are identified and conditions reversed, the cost burden in Australia alone will exceed one percent of gross domestic product (GDP) in the next 20 years,” Professor Bruce Milthorpe, Dean of the Faculty of Science at UTS said.

“Through Professor Vissel’s appointment, we hope to create new exciting opportunities for neuroscience and for regenerative medicine,” Professor Milthorpe said. “Our increasing investment in this area recognises the social importance and need not only for the health of Australians, but also for UTS students who will be leading influencers of the future and who must be at the forefront of this area of science and health.”

Professor Vissel brings a record of accomplishments to UTS. After being awarded his PhD in medical genetics from the University of Melbourne in 1991, Professor Vissel joined Garvan’s Neuroscience Division, where he subsequently was awarded a National Health and Medical Research Council CJ Martin Fellowship to pursue neuroscience research with Professor Stephen Heinemann at the world-leading Salk Institute in San Diego, USA.

He spent 10 years at Salk, where he authored a number of seminal studies describing molecular mechanisms that regulate synaptic function and their role in behaviour and neurological diseases. He also received several prestigious awards – a Human Frontiers Award (1996), a Fulbright Award (1998) and a Lieberman Award (2000).

In late 2002, Professor Vissel returned to Garvan taking up a position as Head of the Neurodegenerative Diseases group in the Neuroscience Division. His team’s work at the Garvan since then has, among other things, provided new insights into synapse function and shown that the brain has far greater potential for regeneration and repair than previously thought.

Professor Vissel is also an important contributor to a number of organisations. He is Chair of the Advisory Board of Cellmid Ltd, a member of the Board of Parkinson’s NSW, and scientific advisor to Alzheimer’s Australia and SpinalCure Australia.

==> picture [536 x 77] intentionally omitted <==

“I have come to UTS because this is a university that aims for novel ways of thinking, for new fresh ideas and approaches and that, above all, values practical outcomes,” Professor Vissel said. “My goal is to develop novel understanding about the science behind brain and spinal cord disorders and to work to bridge the gap between basic science and the urgent need for patient impact. It is an enormous privilege to have been recruited to UTS to contribute to developing this important area.”

With exciting work currently underway, Professor Vissel and his team will continue to stay onsite at Garvan until 2017 before transitioning to UTS, where he will continue to develop and expand his research, while also maintaining collaborative research ties with Garvan.

“In this way, Professor Vissel’s appointment also paves the way for collaborative opportunities on the greater scale between UTS and Garvan,” said Professor Milthorpe.

Media Contact:

Rebecca Gallegos, UTS Science Rebecca.gallegos@uts.edu.au 02 9514 8271 or 0429 483 747